Ποια είναι η τιμή για AP Biosciences Inc (6945)

Η τιμή για AP Biosciences Inc (6945) είναι $3.06

Ποια είναι η κεφαλαιοποίηση αγοράς για AP Biosciences Inc (6945)

Η κεφαλαιοποίηση αγοράς για AP Biosciences Inc (6945) είναι $296.40M

AP Biosciences Inc (6945) Τιμή και Κεφαλαιοποίηση Αγοράς

AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company dedicated to the research and development of bispecific antibody drugs, aiming to fulfill critical unmet medical needs. Its robust pipeline features several promising candidates: Leading the pack, IBI302 is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration (nAMD). Further along, AP505 is undergoing Phase I clinical trials for various solid tumors. AP203, also in Phase I, is being investigated for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous cell carcinomas. In earlier development, AP402 is currently in the pre-clinical research phase, focusing on breast cancer patients. Additionally, AP601 is also in pre-clinical research, targeting a broader spectrum of malignancies including lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. Founded in 2013, the company maintains its headquarters in Taipei City, Taiwan.

Η τιμή για 6945	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$54,226.46 $296.40M	NVDA	$5.260T	+1,774,392.01%
$49,266.56 $296.40M	AAPL	$4.779T	+1,612,085.39%
$41,412.51 $296.40M	GOOG	$4.017T	+1,355,071.84%
$38,346.00 $296.40M	MSFT	$3.719T	+1,254,724.12%
$28,189.95 $296.40M	AMZN	$2.734T	+922,380.34%

Η τιμή για 6945

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$54,226.46 $296.40M